Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHBP | P24387 | 1/20 | 0.49 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.49 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.49 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.49 |
| ▸ | NQO2 | P16083 | 4/20 | 0.41 |
| ▸ | POLB | P06746 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.35 |
| ▸ | MEN1 | O00255 | 4/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.35 |
| ▸ | NPC1 | O15118 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | MMP14 | P50281 | 2/20 | 0.33 |
| ▸ | BLM | P54132 | 2/20 | 0.33 |
| ▸ | CASP6 | P55212 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6674064 | 0.80 | TSHR (0.45) | CRHBPCRHR2KEAP1NFE2L2NQO2 | |
| SCHEMBL6678874 | 0.77 | CRHBP (0.52) | CRHBPCRHR2KEAP1NFE2L2POLB | |
| SCHEMBL11653613 | 0.77 | TLR8 (0.41) | CRHBPCRHR2KEAP1NFE2L2ALDH1A1 | |
| SCHEMBL6676223 | 0.77 | CRHBP (0.40) | CRHBPCRHR2KEAP1NFE2L2NQO2 | |
| SCHEMBL11602714 | 0.76 | MAT2A (0.46) | CRHBPCRHR2KEAP1NFE2L2ALDH1A1 | |
| SCHEMBL6676030 | 0.74 | PDE5A (0.41) | CRHBPCRHR2KEAP1NFE2L2MEN1 | |
| SCHEMBL6674365 | 0.74 | CRHBP (0.39) | CRHBPCRHR2KEAP1NFE2L2NQO2 | |
| SCHEMBL11175047 | 0.74 | LTA4H (0.42) | CRHBPCRHR2KEAP1NFE2L2POLB | |
| SCHEMBL5066814 | 0.73 | TDP1 (0.38) | CRHBPCRHR2KEAP1NFE2L2POLB | |
| SCHEMBL1651160 | 0.73 | PDPK1 (0.42) | CRHBPCRHR2KEAP1NFE2L2NQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1468688-A2 | Benzoazine mono-N-oxides and benzoazine 1,4 dioxides and compositions therefrom for the therapeutic use in cancer treatments | Auckland Uniservices Limited (NZ) | 2004-10-20 | — | — | EP | claimed |
| US-20040192686-A1 | Benzoazine mono-N-oxides and benzoazine 1,4 dioxides and compositions therefrom for the therapeutic use in cancer treatments | AUCKLAND UNISERVICES LIMITED (NZ) | 2004-09-30 | — | — | US | claimed |
| EP-1468688-A2 | Benzoazine mono-N-oxides and benzoazine 1,4 dioxides and compositions therefrom for the therapeutic use in cancer treatments | Auckland Uniservices Limited (NZ) | 2004-10-20 | — | — | EP | disclosed |
| US-20040192686-A1 | Benzoazine mono-N-oxides and benzoazine 1,4 dioxides and compositions therefrom for the therapeutic use in cancer treatments | AUCKLAND UNISERVICES LIMITED (NZ) | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192686-A1 | Benzoazine mono-N-oxides and benzoazine 1,4 dioxides and compositions therefrom for the therapeutic use in cancer treatments | NPM1, DUOX1, NOX5 | CRHBP 4700/4885CRHR2 3115/4885KEAP1 412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.